Blurbs

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Seagen (SGEN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MannKind (MNKDResearch Report) and Seagen (SGENResearch Report) with bullish sentiments.

MannKind (MNKD)

In a report issued on May 23, Thomas Smith from SVB Securities reiterated a Buy rating on MannKind, with a price target of $5.00. The company’s shares closed last Tuesday at $4.00.

According to TipRanks.com, Smith ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -29.6% and a 16.8% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MannKind with a $5.60 average price target, a 33.7% upside from current levels. In a report issued on May 23, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $6.50 price target.

See today’s best-performing stocks on TipRanks >>

Seagen (SGEN)

SVB Securities analyst Andrew Berens maintained a Buy rating on Seagen on May 23. The company’s shares closed last Tuesday at $133.47.

According to TipRanks.com, Berens is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.9% and a 38.7% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.

Currently, the analyst consensus on Seagen is a Strong Buy with an average price target of $165.14, representing a 19.0% upside. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $157.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MNKD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos